FNY Partners Fund’s Sage Therapeutics SAGE Stock Holding History

FNY Partners Fund’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-1,000	Closed	-$58.6K	–	1513
2016 Q4	$51K	Buy	+1,000	New	+$47.1K	﹤0.01%	295

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FNY Partners Fund's SAGE Position: Q1 2017 in Review

FNY Partners Fund sold out of Sage Therapeutics (SAGE) in Q1 2017, closing a stake of 1,000 shares — an estimated $58.6K sold.

FNY Partners Fund first reported a position in SAGE in Q4 2016 and held it in 1 quarter. The position peaked at $51K in Q4 2016. 190 funds tracked by Wall St. Rank hold SAGE as of Q1 2017.

FNY Partners Fund reported no remaining Sage Therapeutics position as of Q1 2017 after selling out during the quarter.
FNY Partners Fund sold 1,000 Sage Therapeutics shares in Q1 2017, an estimated $58.6K.
FNY Partners Fund first reported a position in Sage Therapeutics in Q4 2016 and held it in 1 quarter.
FNY Partners Fund's Sage Therapeutics position peaked at $51K in Q4 2016.
190 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2017.

Based on FNY Partners Fund's 13F filing for Q1 2017, filed 15 May 2017.